- Contraception For Teens: Let's Talk About It
- Gounder Gives Lowdown on Ebola, Peptides, and Colorectal Screenings
- ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
- ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
- 6 dental technology updates in May
- From clinician to leader: Building confidence, capability and leadership in dentistry
- Operationalizing AI at scale: A practical framework for enterprise-scale success
- 3 key stats on the orthodontist workforce
- Meet the COOs of 10 specialty DSOs
- Data, cross-training, and pipeline development: How health systems are rethinking OR staffing
- How top health systems are redefining the digital patient experience
- ‘The most significant change in 20 years’: Cancer centers prepare for daraxonrasib demand
- A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
- Budget-Strapped Montana Will Stress-Test Trump’s Medicaid Work Rules
- How CEOs actually use hospital rankings — and when they don’t
- What OU Health’s founding CEO learned building a new health system
- Arkansas hospital CEO to step down after 11 years for new role
- The behavioral health workforce pipeline: Where it stands and where it’s headed
- 6 major investments in youth behavioral health
- Coalition for Health AI unveils governance playbook for systems
- 66 health systems ranked by long-term debt
- UnitedHealthcare drops some prior auth requirements for cardiology, orthopedic services
- 8 No Surprises Act shake-ups physicians need to know
- The ASC independence playbook: 3 leaders’ thoughts
- Dr. Rahimah Maina opens new dental practice
- GWU offloaded its $450M physician group problem — why the industry watching
- The gastroenterologist pay gap
- Texas surgery center to double in size, add 2 ORs
- What dental leaders told us in May
- Climate Change: Statement on Proposed Rescission of Climate-Related Disclosure Rules
- Kenyan Court Blocks Trump's Plan To Quarantine Ebola Patients
- What’s going on at the FTC? 3 notes for ASC leaders
- 8 DSOs making headlines
- The physician noncompete battle in 5 key figures
- The physician red flags that can predict a bad ASC partner
- Patient death draws renewed CMS scrutiny at HCA’s Mission Hospital
- Nearly 70% of US counties lack a GI: 13 concerning workforce stats
- Statement of Commissioner Mark T. Uyeda on the Rescission of Climate-Related Disclosure Rules
- A new behavioral health profession is born
- Keynote Remarks at the 2026 Reagan National Economic Forum
- Statement on Proposing Release for Rescission of Climate-Related Disclosure Rules
- Dentists’ pay climbed the most in these 10 states
- Mental Health Disorders Now No. 1 Cause of Disability Worldwide
- Massachusetts AG sues UnitedHealthcare over alleged Medicaid fraud
- UnitedHealthcare to nix nearly two thirds of pediatric prior auths
- Industry Voices—Patients are building a new healthcare system. The industry is finally catching up
- Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
- Study: LA Canine Outbreak Caused By Low Vaccination Rates, Crowded Boarding
- Ocrelizumab Effective In Slowing Progressive MS, Trial Shows
- Long COVID Might Be Twice As Common As Previously Thought
- In Vaccine-Skeptical California County, A Potential Playbook To Contain Measles
- Heavy Drinking Harms College Students' Brain Power, Study Finds
- A Trump Stronghold Grapples With Health Risks of ICE Detention Sites
- After Her Bout of Amnesia, a $59,000 Billing Dispute Wouldn’t Go Away
- Pharma urged to modernize patient support as young adult cancer rates rise
- Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties
- MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
- Aetna to launch ‘on demand’ virtual mental health services in 2027
- U of Connecticut dental school reappoints dean for 2nd term
- Michigan dentist charged with Medicaid fraud
- Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
- Acadia in the headlines: 6 things to know
- 26 behavioral health executive moves to know
- AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
- Advocate Health grows Q1 revenue by 10.8% amid higher volumes, greater efficiency
- Behavioral health hospital operator to pay $32M in Medicare fraud settlement
- Bangladesh Measles Surge Kills 500+ Children; Vaccine Delays Blamed
- Care navigation startup Garner Health banks $100M series E at $2.74B valuation
- HCA bolsters workforce pipeline with healthcare professional college acquisition
- Plant-Based Diet May Cut Obesity Risk For Women In Menopause
- Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
- Penn Medicine, K Health partner to deploy AI clinical agents
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CMS finalizes changes to No Surprises Act dispute resolution process
- Smartwatch App Accurately Detects Major Epileptic Seizures
- Racial Gap Exists For Asthma Inhaler Use
- New Colon Cancer Screening Guidelines Add Blood And At-Home Tests
- Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
- CVS expands partnership with Salesforce for greater call center personalization
- Nurse Convicted In Patient's Death Turns Fatal Drug Error Into Cautionary Tale
- Wearable Ultrasound Patch Monitors High-Risk Pregnancies In Real Time
- Listen to the Latest ‘KFF Health News Minute’
- In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
- Teladoc Health inks partnership with Walmart to expand virtual care services
- PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion
- Kaléo speaks up on allergy awareness to amplify patient stories
- Privacy and PetShops: Remarks at the Regulatory PETshop Series: Cryptographic Technologies and Financial Services Regulation
- NYC Health + Hospitals adds 2nd behavioral health housing site
- Mindfulness isn’t a perk anymore — it’s a workforce strategy
- With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
- Hospitals again ask FTC, DOJ for exemption from expanded premerger notification filings
- Coalition for Health AI unveils governance playbooks for responsible AI adoption
- Amazon taps Roy Schoenberg to lead healthcare business as Neil Lindsay plans to step down
- Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
- U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy
- CAT on a Hot Tin Roof
- GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers
- GoodRx launches subscription program for low-cost generic medications, telehealth services
- George Washington University locks deal to hand off debt-ridden physician practice to UHS
- Humana invests $83M in new Florida pharmacy distribution center
- As J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey
- ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
- An insider’s look at LillyDirect
- GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
- Weight-Loss Program Helps Women Battling Breast Cancer
- Younger U.S. Women of Color Face Rising Breast Cancer Deaths
- High Fitness Doesn’t Raise A-fib Risk In Young Men, Study Finds
- Cheaper, Alternative Health Plans Are Having A Moment, But Critics Urge Caution
- Ultrafine Wildfire Smoke Particles May Pose Serious Health Risks
- Montana Hurries To Adopt Trump’s Medicaid Work Rules Amid Budget Woes
- Readers Address Drugged Driving, Suicide Prevention, Worker Shortages
- Nurse Convicted in Patient’s Death Turns Fatal Drug Error Into a Cautionary Tale
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
- FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
- Eli Lilly wins argument over Noom’s GLP-1 dosing claims
- Remarks at the Stanford Rock Center for Corporate Governance
- Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
- Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
- JD Power: Cost pressures worsen member experience with commercial plans
- Trump Admin Bars Key U.S. Researchers From Global Virus Response Talk
- Listen to the Latest ‘KFF Health News Minute’
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
- Everyone Has A Family Doc, But Can You Get An Appointment?
- Many U.S. College Students With Psychosis Are Not Receiving Treatment
- Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids
- Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds
- Dust Yields Clues to Viral Outbreaks, Study Finds
- 3 Medical Routines That Older People May Not Need
- Acting NIAID Chief Steps Down Amid Ebola, Hantavirus Concerns
- Sunscreen Confusion Puts More Americans At Risk For Melanoma
- 1 In 10 U.S. Surgeons Quit Practice, Study Warns Of Shortage
- Video Game Can Detect Depression In Minutes, Study Says
- Quitting Smoking Might Lower Your Dementia Risk
- Severe Asthma Often Comes With Other Serious Health Problems
- Efforts To Understand The Nation's Drugged Driving Problem Stall Under Trump
- RFK Jr. Fires Two Leaders Of Major U.S. Health Task Force
- Common Food Preservatives Linked to Major Heart Problems
- Migraine With Aura Linked To Middle-Age Stroke Risk
- Nicotine Vapes Triple Smokers' Odds Of Quitting Tobacco
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- The failure of the ‘usual suspects’ approach to life science recruitment
- The failure of the ‘usual suspects’ approach to life science recruitment
- Statement on Novel Exchange-Traded Funds (ETFs)
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
Acting Centers for Disease Control and Prevention (CDC) Director Jim O’Neill is quite a change from the recently departed Dr. Susan Monarez:
CDC's acting director tells staff to treat Americans 'as adults who can make their own informed decisions'
In an email, Jim O’Neill said the agency is experiencing "mission creep."
By Will McDuffie and Dr. Mark Abdelmalek - September 17, 2025In an email welcoming CDC staff back to the office weeks after a gunman fired bullets at the agency’s headquarters, acting Centers for Disease Control and Prevention Director Jim O’Neill wrote Tuesday that the agency had lost the trust of Americans and was experiencing "mission creep" that has led it to be too involved in Americans’ health decisions.
In the email, dated Tuesday and obtained by ABC News, O’Neill told CDC staff he hoped their "return is going smoothly" and noted "enhanced security and repairs to the Roybal campus" in Atlanta, Georgia.
He praised CDC's accomplishments from decades ago, including its combating of malaria and HIV, and noted its work this year on the measles outbreak in Texas and an Ebola outbreak in Africa.
But O'Neill made clear that Health and Human Services Secretary Robert F. Kennedy Jr. is now demanding a different approach from the CDC -- one by which the agency reduces its role in Americans’ lives.
"Mission creep has distracted us from our core mission over the years," O’Neill wrote. "Not every health decision is the government’s business, and CDC need not duplicate the work of other divisions."
O’Neill, the HHS deputy secretary whom Kennedy appointed to be CDC’s acting director after Susan Monarez’s dismissal last month, said the agency had "lost the American public trust and faith" during the pandemic but that HHS’ new leadership is "working hard to refocus and earn that trust back."
"Rigorous science, transparency about data and reasoning, and treating our fellow citizens as adults who can make their own informed decisions will be well received whenever we can offer them," he added.
Technically, the CDC only offers guidance and does not have the ability to mandate people’s behavior; things such as school vaccine mandates, for instance, are decided upon and implemented at the state level.
Fiona Havers, a former CDC official who worked on vaccine policy, told ABC News, “CDC has always treated Americans like adults by providing them with the science-based evidence and guidance they need to make their own decisions."
In his email, O’Neill urged staff to "think big. What is the 2026 equivalent of eradicating malaria? What might a CDC, unconstrained by WHO, look like? Where can I apply the principle of radical transparency to my work?"
President Donald Trump signed an executive order in January withdrawing the United States from the World Health Organization (WHO).
O’Neill’s email came on the eve of Monarez’s highly anticipated public hearing Wednesday in front of the Senate health committee, during which she alleged that Kennedy demanded that she approve "in advance" modified vaccine recommendations by an independent panel that Monarez testified were unsupported by scientific evidence or other data.
Monarez also testified in her opening statement that Kennedy directed her to "dismiss career officials responsible for vaccine policy without cause."
Monarez testified, "I was fired for holding the line on scientific integrity."
An HHS spokesperson later said Monarez’s testimony had "factual inaccuracies and left out important details," and described her dismissal as a consequence of her acting "maliciously to undermine the President’s agenda and was fired as a result."
The AP backgrounder on Jim O’Neill:
https://apnews.com/article/jim-oneill-cdc-kennedy-trump-vaccines-58fd24f678bf46ea6ec96a2b09f85ff4
Trump’s new CDC chief: A Washington health insider with a libertarian streak
By Matthew Perrone, August 29, 2025WASHINGTON (AP) — Jim O’Neill, a former investor, critic of health regulations and Health Secretary Robert F. Kennedy Jr.’s deputy, is taking control of the Centers for Disease Control and Prevention following a tumultuous week in which the agency’s director was forced out.
O’Neill was picked by President Donald Trump to be the CDC’s interim director, supplanting Susan Monarez, a longtime government scientist.
Monarez had been the CDC director for less than a month. Her lawyers said she refused “to rubber-stamp unscientific, reckless directives and fire dedicated health experts.”
O’Neill takes over an agency that has been rocked by firings, resignations and efforts by Kennedy to reshape the nation’s vaccine policies to match his long-standing suspicions about the safety and effectiveness of long-established shots.
O’Neill said Friday afternoon in a social media post that he looked forward to working with CDC staff and “announcing additions to the senior leadership in the weeks ahead.” He added that he would continue to serve as HHS deputy.
A former associate of billionaire tech entrepreneur Peter Thiel, O’Neill previously helped run one of Thiel’s investment funds and later managed several of his other projects. Those included a nonprofit working to develop manmade islands that would float outside U.S. territory, allowing them to experiment with new forms of government.
He has no training in medicine or health care and holds bachelor’s and master’s degrees in humanities.
A Washington insider on a team of outsiders
O’Neill has kept a markedly lower profile than Trump’s other top health officials, all of whom joined the administration as Washington outsiders. He’s also the only one with experience working at HHS, where he served for six years under President George W. Bush.
Those who know him say he’ll likely be tasked with trying to calm the situation at CDC — though it’s unclear what, if any, independence he’ll have from Kennedy.
“Jim O’Neill is a health care policy professional and I don’t think anybody can accuse him of being an RFK Jr. sock puppet,” said Peter Pitts, a former FDA official under Bush. “The question becomes whether the role of CDC director becomes a strictly paper tiger position, where the person only does what they’re told to by the secretary.”
O’Neill is not closely associated with Kennedy’s “ Make America Healthy Again ” movement and its efforts against food dyes, fluoride and ultraprocessed foods.
He was also not a major critic of public health measures during the pandemic, unlike Food and Drug Administration chief Marty Makary and other several Trump officials. Although O’Neill did use social media to criticize FDA efforts to stop the prescribing of unproven treatments for COVID-19, including the anti-parasite drug ivermectin.
O’Neill has pushed for less regulation
O’Neill has long-standing ties to the libertarian wing of the Republican Party, including Thiel, one of Trump’s leading supporters from Silicon Valley. Like Thiel, O’Neill has expressed disdain for many parts of the federal bureaucracy, saying it hinders advances in medicine, technology and other areas.
During Trump’s first term, O’Neill was vetted as a possible choice to lead the FDA, although his past statements about the agency raised alarms among pharmaceutical and medical technology executives.
In particular, O’Neill proposed doing away with FDA’s 60-year-old mandate of assuring new drugs are both safe and effective in treating disease. In a 2014 speech, O’Neill suggested drug effectiveness could be established after medicines hit the market.
Trump ultimately nominated Dr. Scott Gottlieb, a former FDA official and supporter of the agency’s regulatory approach, as commissioner.
Refusal to break with Kennedy on vaccines
After being nominated to the HHS post, O’Neill voiced his support for the federal government’s traditional system for overseeing vaccines — including the role of the CDC — while refusing to criticize Kennedy’s views on the topic.“I support CDC’s recommendations for vaccines,” O’Neill told Louisiana Republican Sen. Bill Cassidy at a confirmation hearing in June. “I think that’s a central role that CDC has. It’s mandated in law.”
In follow-up questions, Democrat Ron Wyden pressed O’Neill on statements by Kennedy downplaying the safety and effectiveness of vaccines to prevent measles and other diseases.
“Secretary Kennedy has not made it difficult nor discouraged people from taking vaccines,” O’Neill responded.
High-stakes vaccine decisions ahead
Within weeks, O’Neill could be asked to sign off on new recommendations from a CDC panel that Kennedy has reshaped with vaccine skeptics. The group is scheduled to meet next month to review vaccinations for measles, hepatitis and other conditions that have long been established on the government immunization schedule for children.
Traditionally, the CDC director signs off on recommendations from the panel. But Monarez was ousted after, among other things, she refused to automatically sign off the committee’s recommendations, according to Dr. Richard Besser, a former CDC acting director who spoke to her.
As an acting official, federal law limits O’Neill to no more than 210 days heading the agency before he must step aside or be formally nominated to the post.
Dr. Anne Schuchat, who served twice as acting CDC director, says there are essentially no limits on the powers of acting agency chiefs, beyond the time contraints.
“I was told, ‘You’re the director. Do what you need to do,’” Schuchat said.
Dueling health roles
Both of O’Neill’s roles at HHS and CDC are demanding, full-time jobs that would be extremely challenging for one person to do simultaneously, Schuchat said.
“But if the goal is to have an acting CDC director fulfill a predetermined decision about vaccines, it’s a different story,” Schuchat said.
It won’t help O’Neill that there was an exodus this week of four veteran CDC center directors, leaving the agency with few leaders who have a background in medicine, science or public health crisis management, she added.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















